The Journal of Pain
Volume 11, Issue 4 , Pages 303-311 , April 2010

ALO-01 (Morphine Sulfate and Naltrexone Hydrochloride) Extended-Release Capsules in the Treatment of Chronic Pain of Osteoarthritis of the Hip or Knee: Pharmacokinetics, Efficacy, and Safety

  • Nathaniel Katz

      Affiliations

    • Tufts University School of Medicine, Boston, Massachusetts
    • Analgesic Research, Needham, Massachusetts
    • Corresponding Author InformationAddress reprint requests to Dr Nathaniel Katz, Analgesic Research, 109 Highland Avenue, Suite 2B, Needham, MA 02494.
    • ,
  • Stephen Sun

      Affiliations

    • Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc, Bridgewater, New Jersey
    • ,
  • Franklin Johnson

      Affiliations

    • Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc, Bridgewater, New Jersey
    • ,
  • Joseph Stauffer

      Affiliations

    • Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc, Bridgewater, New Jersey
    • Johns Hopkins University School of Medicine, Baltimore, Maryland

Received 28 October 2008 ,Revised 2 July 2009 ,Accepted 28 July 2009.

References 

  1. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–514
  2. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee: Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039–1049
  3. Bashaw ED, Kaiko RF, Grandy RP, Reder RF, Goldenheim PD. Relative bioavailability of controlled-release morphine sulfate during naltrexone blockade. Int J Clin Pharmacol Ther. 1995;33:524–529
  4. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–1840
  5. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138
  6. Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: Evolving pseudoscience on the Internet. Drug Alcohol Depend. 2006;83(Suppl 1):S31–S39
  7. Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm. 1984;3:273–280
  8. Gourlay GK. Sustained relief of chronic pain: Pharmacokinetics of sustained release morphine. Clin Pharmacokinet [abstract 235]. 1998;173–190
  9. Johnson FK, Ciric S, Boudriau S, Swearingen D, Stauffer J: Effect of food and sprinkling of pellets on applesauce on the pharmacokinetics of ALO-01 [abstract 99]. Presented at: 2008 American Association of Pharmaceutical Scientists Annual Meeting and Exposition; Atlanta, GA
  10. Jones J, Johnson F, Wagner G, Stauffer J, Sellers E. Evaluation of abuse potential of ALO-01, and extended release morphine sulfate plus sequestered naltrexone formulation, among recreational opioid users. J Pain [abstract 235]. 2008;9(4 Suppl 2):34
  11. KADIAN Capsules [Package Insert]. Morristown, NJ, Actavis US; 2008
  12. Kaiko RF, Grandy RP, Reder RF, Goldenheim PD, Sackler RS. A bioequivalence study of oral controlled-release morphine using naltrexone blockade. J Clin Pharmacol. 1995;35:499–504
  13. Katz N, Sun S, Fox L, Johnson F, Wagner G, Stauffer J. Efficacy and safety evaluation of an extended-release morphine sulfate formulation with sequestered naltrexone for the treatment of osteoarthritis. J Pain. 2008;9(Suppl 2):41
  14. Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, et al. Foundations of opioid risk management. Clin J Pain. 2007;23:103–118
  15. Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23:648–660
  16. Kuehn BM. Scientists probe ways to curb opioid abuse without hindering pain treatment. JAMA. 2007;297:1965–1967
  17. Lipman AG, Jackson KC II: Opioid pharmacotherapy, in Warfield CA, Bajwa ZH (eds): Principles and Practices of Pain Medicine. New York, NY, 2004, pp 583-600
  18. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: Pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8:181–186
  19. National Institute for Health and Clinical Excellence: Naltrexone for the Management of Opioid Dependence. London, UK, National Institute for Health and Clinical Excellence, 2007, pp 1-28
  20. Resnick RB, Volvavka J, Freedman AM, Thomas M. Studies of EN-1639A (naltrexone): A new narcotic antagonist. Am J Psychiatry. 1974;131:646–650
  21. ReVia naltrexone hydrochloride, product monograph. Pomona, NY, Duramed Pharmaceuticals, Inc, 2003
  22. ReVia [package insert]. Montvale, NJ: Barr Pharmaceuticals, Inc; 2007;
  23. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv. 2006;3:489–497
  24. Substance Abuse and Mental Health Services Administration . Results from the 2007 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, NSDUH Series H-34, DHHS Publication No. SMA 08-4343; 2008;
  25. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER): Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. 2001
  26. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER): Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations; Revision 1. 2003
  27. Verebey K. The clinical pharmacology of naltrexone: Pharmacology and pharmacodynamics. In:  Willette RE,  Barnett G editor. Naltrexone Pharmacochemistry and Sustained Release Preparations: Research Monograph. Rockville, MD, National Institute on Drug Abuse; 1981;p. 147–158
  28. Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: Potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Invest Drugs. 2004;5:61–66
  29. Wright C, Kramer ED, Zalman MA, Smith MY, Haddox JD. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend. 2006;83(Suppl 1):S68–S76

 Supported by King Pharmaceuticals, Inc, Bridgewater, New Jersey.

PII: S1526-5900(09)00696-8

doi: 10.1016/j.jpain.2009.07.017

The Journal of Pain
Volume 11, Issue 4 , Pages 303-311 , April 2010

Article Tools

* Image Usage & Resolution